Literature DB >> 24801812

Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma.

Jacob H Rasmussen1, Ivan R Vogelius1, Barbara M Fischer2, Jeppe Friborg1, Marianne C Aznar1, Gitte F Persson1, Katrin Håkansson1, Claus A Kristensen1, Søren M Bentzen3, Lena Specht1.   

Abstract

BACKGROUND: The prognostic value of 18F-Fludeoxyglucose (FDG) uptake could be due to its association with already known clinical risk factors.
METHODS: Correlation between FDG uptake metrics and other known risk factors from 287 patients were analyzed. Time to any failure was analyzed using Cox proportional hazards model stratified by tumor subsite. The resulting multivariate prognostic model was used to generate a table of 2-year freedom from failure estimates with confidence intervals (CIs).
RESULTS: Increasing values of standardized uptake value maximum (SUVmax) correlated with other known risk factors. The reduced Cox model included SUVmax (hazard ratio [HR] = 1.34), cisplatin (HR = 0.37), smoking status (HR = 1.49), and gross target volume (GTV; HR = 1.74) as significant prognostic factors. Including SUVmax in the model changed the 2-year failure estimate by more than 10% for a quarter of the patients (23%).
CONCLUSION: FDG uptake retains statistical significance in a multivariate analysis and has clinically relevant prognostic impact. We developed a prognostic model for risk stratification of patients in a clinical setting.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  18F-Fludeoxyglucose; Cox model; prognostic value; radiotherapy; squamous cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 24801812     DOI: 10.1002/hed.23745

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

1.  Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR.

Authors:  J H Rasmussen; B M Fischer; M C Aznar; A E Hansen; I R Vogelius; J Löfgren; F L Andersen; A Loft; A Kjaer; L Højgaard; L Specht
Journal:  Br J Radiol       Date:  2015-01-30       Impact factor: 3.039

2.  Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers.

Authors:  Feifei Teng; Madhava Aryal; Jae Lee; Choonik Lee; Xioajin Shen; Peter G Hawkins; Michelle Mierzwa; Avraham Eisbruch; Yue Cao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-21       Impact factor: 7.038

3.  Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study.

Authors:  Louise M Risør; Malene M Clausen; Zaza Ujmajuridze; Mohammed Farhadi; Kim F Andersen; Annika Loft; Jeppe Friborg; Andreas Kjaer
Journal:  J Nucl Med       Date:  2021-12-02       Impact factor: 11.082

Review 4.  Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.

Authors:  Xin Yu; Heyi Zheng; Matthew Tv Chan; William Kk Wu
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

Review 5.  What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis.

Authors:  Pierluigi Bonomo; A Merlotti; E Olmetto; A Bianchi; I Desideri; A Bacigalupo; P Franco; C Franzese; E Orlandi; L Livi; S Caini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-09       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.